BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chen YM, Huang WN, Wu YD, Lin CT, Chen YH, Chen DY, Hsieh TY. Reactivation of hepatitis B virus infection in patients with rheumatoid arthritis receiving tofacitinib: a real-world study. Ann Rheum Dis. 2018;77:780-782. [PMID: 28663308 DOI: 10.1136/annrheumdis-2017-211322] [Cited by in Crossref: 33] [Cited by in F6Publishing: 24] [Article Influence: 6.6] [Reference Citation Analysis]
Number Citing Articles
1 Zhang W, Li X, Chen B, Zhang J, Torres-culala KMT, Zhou C. Oral Tofacitinib and Systemic Corticosteroids, Alone or in Combination, in Patients With Moderate-to-Severe Alopecia Areata: A Retrospective Study. Front Med 2022;9:891434. [DOI: 10.3389/fmed.2022.891434] [Reference Citation Analysis]
2 Axiaris G, Zampeli E, Michopoulos S, Bamias G. Management of hepatitis B virus infection in patients with inflammatory bowel disease under immunosuppressive treatment. World J Gastroenterol 2021; 27(25): 3762-3779 [PMID: 34321842 DOI: 10.3748/wjg.v27.i25.3762] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
3 Agrawal M, Kim ES, Colombel JF. JAK Inhibitors Safety in Ulcerative Colitis: Practical Implications. J Crohns Colitis 2020;14:S755-60. [PMID: 32006031 DOI: 10.1093/ecco-jcc/jjaa017] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 10.0] [Reference Citation Analysis]
4 Kordzadeh-Kermani E, Khalili H, Karimzadeh I, Salehi M. Prevention Strategies to Minimize the Infection Risk Associated with Biologic and Targeted Immunomodulators. Infect Drug Resist 2020;13:513-32. [PMID: 32110062 DOI: 10.2147/IDR.S233137] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
5 Harigai M, Winthrop K, Takeuchi T, Hsieh TY, Chen YM, Smolen JS, Burmester G, Walls C, Wu WS, Dickson C, Liao R, Genovese MC. Evaluation of hepatitis B virus in clinical trials of baricitinib in rheumatoid arthritis. RMD Open. 2020;6. [PMID: 32098857 DOI: 10.1136/rmdopen-2019-001095] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 14.0] [Reference Citation Analysis]
6 Huang JX, Zhang LJ. Successful treatment of tofacitinib in a case with rheumatoid arthritis who experienced hepatitis B virus reactivation induced by tocilizumab and recovered from entecavir rescue therapy. Arch Rheumatol 2021;36:458-60. [PMID: 34870178 DOI: 10.46497/ArchRheumatol.2021.8230] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Barnhill MS, Steinberg JM, Jennings JJ, Lewis JH. Hepatotoxicty of Agents Used in the Management of Inflammatory Bowel Disease: a 2020 Update. Curr Gastroenterol Rep 2020;22:47. [PMID: 32671616 DOI: 10.1007/s11894-020-00781-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
8 Akiyama S, Cotter TG, Sakuraba A. Risk of hepatitis B virus reactivation in patients with autoimmune diseases undergoing non-tumor necrosis factor-targeted biologics. World J Gastroenterol 2021; 27(19): 2312-2324 [PMID: 34040324 DOI: 10.3748/wjg.v27.i19.2312] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
9 Ezeonwumelu IJ, Garcia-Vidal E, Ballana E. JAK-STAT Pathway: A Novel Target to Tackle Viral Infections. Viruses 2021;13:2379. [PMID: 34960648 DOI: 10.3390/v13122379] [Reference Citation Analysis]
10 Wu YL, Ke J, Zhang BY, Zhao D. Hepatitis B virus reactivation in rheumatoid arthritis. World J Clin Cases 2022; 10(1): 12-22 [DOI: 10.12998/wjcc.v10.i1.12] [Reference Citation Analysis]
11 Aguirre A, Yazdany J. Hepatitis B Screening Before Biologic or Targeted Synthetic Disease-modifying Antirheumatic Drug Therapy: Many Roads to Improvement. J Rheumatol 2022;49:1-4. [PMID: 34725177 DOI: 10.3899/jrheum.211000] [Reference Citation Analysis]
12 Cheah JT, Faragon JJ, Marks KM. Management of hepatitis B and C infections in rheumatologic disease. Best Pract Res Clin Rheumatol 2018;32:848-68. [PMID: 31427059 DOI: 10.1016/j.berh.2019.04.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
13 Magro F, Estevinho MM. Is tofacitinib a game-changing drug for ulcerative colitis? United European Gastroenterol J 2020;8:755-63. [PMID: 32552501 DOI: 10.1177/2050640620935732] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
14 Calvet X, Carpio D, Rodríguez-Lago I, García-Vicuña R, Barreiro-de-Acosta M, Juanola X, Aguas M, Castillo C, Gratacós J. Risk of infection associated with Janus Kinase (JAK) inhibitors and biological therapies in inflammatory intestinal disease and rheumatoid arthritis. Prevention strategies. Gastroenterol Hepatol 2021:S0210-5705(21)00056-X. [PMID: 33640469 DOI: 10.1016/j.gastrohep.2021.01.007] [Reference Citation Analysis]
15 Zhou Q, Zhang Q, Wang K, Huang T, Deng S, Wang Y, Cheng C. Anti-rheumatic Drug-induced Hepatitis B Virus Reactivation and Preventive Strategies for Hepatocellular Carcinoma. Pharmacol Res 2022;:106181. [PMID: 35301112 DOI: 10.1016/j.phrs.2022.106181] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Yip TC, Gill M, Wong GL, Liu K. Management of hepatitis B virus reactivation due to treatment of COVID-19. Hepatol Int 2022. [PMID: 35235148 DOI: 10.1007/s12072-022-10306-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Koutsianas C, Thomas K, Vassilopoulos D. Reactivation of hepatitis B virus infection in rheumatic diseases: risk and management considerations. Ther Adv Musculoskelet Dis. 2020;12:1759720X20912646. [PMID: 32206094 DOI: 10.1177/1759720x20912646] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
18 Click B, Regueiro M. A Practical Guide to the Safety and Monitoring of New IBD Therapies. Inflamm Bowel Dis. 2019;25:831-842. [PMID: 30312391 DOI: 10.1093/ibd/izy313] [Cited by in Crossref: 21] [Cited by in F6Publishing: 14] [Article Influence: 10.5] [Reference Citation Analysis]
19 Aghbash PS, Eslami N, Shirvaliloo M, Baghi HB. Viral coinfections in COVID-19. J Med Virol 2021;93:5310-22. [PMID: 34032294 DOI: 10.1002/jmv.27102] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
20 Richez C, Morel J, Cornec D, Daïen C, Goupille P, Lazaro E, Lequerré T, Nocturne G, de Lédinghen V, Le Goff B, Pourcher V, Prati C, Seror R, Tournadre A, Truchetet ME, Sibilia J, Pham T. Practical management of patients on Janus kinase inhibitor (JAKi) therapy: Practical fact sheets drawn up by the Rheumatism and Inflammation Club (CRI), a group endorsed by the French Society for Rheumatology (SFR). Joint Bone Spine 2019;86 Suppl 1:eS2-eS103. [PMID: 31791545 DOI: 10.1016/S1297-319X(19)30154-X] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.7] [Reference Citation Analysis]
21 Hu X, Li J, Fu M, Zhao X, Wang W. The JAK/STAT signaling pathway: from bench to clinic. Signal Transduct Target Ther 2021;6:402. [PMID: 34824210 DOI: 10.1038/s41392-021-00791-1] [Reference Citation Analysis]
22 Álvaro-Gracia JM, García-Llorente JF, Valderrama M, Gomez S, Montoro M. Update on the Safety Profile of Tofacitinib in Rheumatoid Arthritis from Clinical Trials to Real-World Studies: A Narrative Review. Rheumatol Ther 2021;8:17-40. [PMID: 33245555 DOI: 10.1007/s40744-020-00258-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
23 Onorato L, Pisaturo M, Camaioni C, Grimaldi P, Codella AV, Calò F, Coppola N. Risk and Prevention of Hepatitis B Virus Reactivation during Immunosuppression for Non-Oncological Diseases. J Clin Med 2021;10:5201. [PMID: 34768721 DOI: 10.3390/jcm10215201] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
24 Ehrenstein B. [Interpretation of tuberculosis and hepatitis screening before immunosuppressive treatment]. Z Rheumatol 2018;77:493-507. [PMID: 29947949 DOI: 10.1007/s00393-018-0488-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
25 Mok CC. Hepatitis B and C infection in patients undergoing biologic and targeted therapies for rheumatic diseases. Best Pract Res Clin Rheumatol 2018;32:767-80. [PMID: 31427054 DOI: 10.1016/j.berh.2019.03.008] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
26 Ito S. Updates on management strategies of hepatitis B virus reactivation in patients with resolved hepatitis virus B infection undergoing immunosuppressive therapy in rheumatology and the current situation in Niigata Rheumatic Center. Mod Rheumatol 2021;31:775-82. [PMID: 33021133 DOI: 10.1080/14397595.2020.1832731] [Reference Citation Analysis]
27 Yerima A, Akintayo R, Adebajo A. Implications of a diagnosis of rheumatoid arthritis in resource-poor countries. Best Pract Res Clin Rheumatol 2021;:101725. [PMID: 34906416 DOI: 10.1016/j.berh.2021.101725] [Reference Citation Analysis]
28 Magrì S, Chessa L, Demurtas M, Cabras F, Mocci G. Review article: safety of new biologic agents for inflammatory bowel disease in the liver. Eur J Gastroenterol Hepatol 2021;33:623-30. [PMID: 33470695 DOI: 10.1097/MEG.0000000000002076] [Reference Citation Analysis]
29 Click B, Regueiro M. Managing Risks with Biologics. Curr Gastroenterol Rep 2019;21:1. [PMID: 30635807 DOI: 10.1007/s11894-019-0669-6] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
30 Wang ST, Tseng CW, Hsu CW, Tung CH, Huang KY, Lu MC, Lai NS. Reactivation of hepatitis B virus infection in patients with rheumatoid arthritis receiving tofacitinib. Int J Rheum Dis 2021;24:1362-9. [PMID: 34506078 DOI: 10.1111/1756-185X.14217] [Reference Citation Analysis]
31 Núñez F P, Castro F, Mezzano G, Quera R, Diaz D, Castro L. Hepatobiliary manifestations in inflammatory bowel disease: A practical approach. World J Hepatol 2022; 14(2): 319-337 [DOI: 10.4254/wjh.v14.i2.319] [Reference Citation Analysis]
32 Garrido I, Lopes S, Macedo G. Hit the Road JAK! The Role of New Oral Treatment in Inflammatory Bowel Disease. Inflamm Bowel Dis 2021:izab037. [PMID: 33742651 DOI: 10.1093/ibd/izab037] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
33 Shi Y, Zheng M. Hepatitis B virus persistence and reactivation. BMJ. 2020;370:m2200. [PMID: 32873599 DOI: 10.1136/bmj.m2200] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
34 Ogawa E, Wei MT, Nguyen MH. Hepatitis B Virus Reactivation Potentiated by Biologics. Infect Dis Clin North Am 2020;34:341-58. [PMID: 32334985 DOI: 10.1016/j.idc.2020.02.009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
35 Chiu YM, Chen DY. Infection risk in patients undergoing treatment for inflammatory arthritis: non-biologics versus biologics. Expert Rev Clin Immunol 2020;16:207-28. [PMID: 31852268 DOI: 10.1080/1744666X.2019.1705785] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]